Articles with public access mandates - Dr Katie EwerLearn more
Available somewhere: 96
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
The Lancet 397 (10269), 99-111, 2021
Mandates: Bill & Melinda Gates Foundation, US National Institutes of Health, UK …
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ...
The Lancet 396 (10249), 467-478, 2020
Mandates: US National Institutes of Health, UK Engineering and Physical Sciences …
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ...
The Lancet 396 (10267), 1979-1993, 2020
Mandates: Swiss National Science Foundation, US National Institutes of Health, UK …
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four …
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
The Lancet 397 (10277), 881-891, 2021
Mandates: Bill & Melinda Gates Foundation, UK Medical Research Council, National …
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial
KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ...
The Lancet 397 (10282), 1351-1362, 2021
Mandates: Swiss National Science Foundation, US National Institutes of Health, UK …
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ...
Nature medicine 27 (2), 270-278, 2021
Mandates: US National Institutes of Health, Versus Arthritis, UK, UK Engineering and …
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
MS Datoo, MH Natama, A Somé, O Traoré, T Rouamba, D Bellamy, ...
The Lancet 397 (10287), 1809-1818, 2021
Mandates: UK Medical Research Council, National Institute for Health Research, UK …
Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial
ID Milligan, MM Gibani, R Sewell, EA Clutterbuck, D Campbell, E Plested, ...
Jama 315 (15), 1610-1623, 2016
Mandates: US National Institutes of Health, National Institute of Health and Medical …
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
KJ Ewer, GA O’Hara, CJA Duncan, KA Collins, SH Sheehy, ...
Nature communications 4 (1), 2836, 2013
Mandates: UK Medical Research Council, Wellcome Trust
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ...
Nature medicine 27 (2), 279-288, 2021
Mandates: UK Medical Research Council, National Institute for Health Research, UK …
A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA
K Ewer, T Rampling, N Venkatraman, G Bowyer, D Wright, T Lambe, ...
New England Journal of Medicine 374 (17), 1635-1646, 2016
Mandates: US National Institutes of Health, Department of International Development …
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ...
The Lancet 398 (10304), 981-990, 2021
Mandates: US National Institutes of Health, UK Engineering and Physical Sciences …
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase …
PM Folegatti, M Bittaye, A Flaxman, FR Lopez, D Bellamy, A Kupke, ...
The Lancet Infectious Diseases 20 (7), 816-826, 2020
Mandates: Department of International Development, UK, National Institute for Health …
ChAd63-MVA–vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans
SH Sheehy, CJA Duncan, SC Elias, P Choudhary, S Biswas, FD Halstead, ...
Molecular Therapy 20 (12), 2355-2368, 2012
Mandates: US National Institutes of Health
Prime-boost vectored malaria vaccines: progress and prospects
AVS Hill, A Reyes-Sandoval, G O’Hara, K Ewer, A Lawrie, A Goodman, ...
Human vaccines 6 (1), 78-83, 2010
Mandates: US National Institutes of Health
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
J Frater, KJ Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ...
The lancet HIV 8 (8), e474-e485, 2021
Mandates: US National Institutes of Health, UK Engineering and Physical Sciences …
Viral vectors as vaccine platforms: from immunogenicity to impact
KJ Ewer, T Lambe, CS Rollier, AJ Spencer, AVS Hill, L Dorrell
Current opinion in immunology 41, 47-54, 2016
Mandates: UK Medical Research Council, National Institute for Health Research, UK …
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial
MS Datoo, HM Natama, A Somé, D Bellamy, O Traoré, T Rouamba, ...
The Lancet Infectious Diseases 22 (12), 1728-1736, 2022
Mandates: UK Medical Research Council, National Institute for Health Research, UK …
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
SH Sheehy, CJA Duncan, SC Elias, KA Collins, KJ Ewer, AJ Spencer, ...
Molecular Therapy 19 (12), 2269-2276, 2011
Mandates: US National Institutes of Health
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
SH Sheehy, CJA Duncan, SC Elias, S Biswas, KA Collins, GA O'Hara, ...
PloS one 7 (2), e31208, 2012
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program